Comparative Infections of Zika, Dengue, and Yellow Fever Viruses in Human Cytotrophoblast-Derived Cells Suggest a Gating Role for the Cytotrophoblast in Zika Virus Placental Invasion.


Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
15 06 2023
Historique:
medline: 19 6 2023
pubmed: 25 5 2023
entrez: 25 5 2023
Statut: ppublish

Résumé

The Zika virus (ZIKV) is teratogenic and considered a TORCH pathogen (toxoplasmosis [Toxoplasma gondii], rubella, cytomegalovirus, herpes simplex virus [HSV], and other microorganisms capable of crossing the blood-placenta barrier). In contrast, the related flavivirus dengue virus (DENV) and the attenuated yellow fever virus vaccine strain (YFV-17D) are not. Understanding the mechanisms used by ZIKV to cross the placenta is necessary. In this work, parallel infections with ZIKV of African and Asian lineages, DENV, and YFV-17D were compared for kinetics and growth efficiency, activation of mTOR pathways, and cytokine secretion profile using cytotrophoblast-derived HTR8 cells and monocytic U937 cells differentiated to M2 macrophages. In HTR8 cells, ZIKV replication, especially the African strain, was significantly more efficient and faster than DENV or YFV-17D. In macrophages, ZIKV replication was also more efficient, although differences between strains were reduced. Greater activation of the mTORC1 and mTORC2 pathways in HTR8 cells infected with ZIKV than with DENV or YFV-17D was observed. HTR8 cells treated with mTOR inhibitors showed a 20-fold reduction in ZIKV yield, versus 5- and 3.5-fold reductions for DENV and YFV-17D, respectively. Finally, infection with ZIKV, but not DENV or YFV-17D, efficiently inhibited the interferon (IFN) and chemoattractant responses in both cell lines. These results suggest a gating role for the cytotrophoblast cells in favoring entry of ZIKV, but not DENV and YFV-17D, into the placental stroma.

Identifiants

pubmed: 37227282
doi: 10.1128/spectrum.00630-23
pmc: PMC10269719
doi:

Substances chimiques

Yellow Fever Vaccine 0
TOR Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0063023

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

J Biol Chem. 2011 Nov 18;286(46):40002-12
pubmed: 21949121
Cell Host Microbe. 2016 Jun 8;19(6):882-90
pubmed: 27212660
Lancet Infect Dis. 2019 Oct;19(10):1138-1147
pubmed: 31559967
PLoS One. 2020 Sep 4;15(9):e0238431
pubmed: 32886677
Int J Infect Dis. 2017 Feb;55:109-112
pubmed: 28088588
Rev Panam Salud Publica. 2018 Jun 05;42:e75
pubmed: 31093103
Int J Infect Dis. 2012 Jan;16(1):e72
pubmed: 21999908
Nat Commun. 2021 Feb 10;12(1):916
pubmed: 33568638
Cell Metab. 2014 Mar 4;19(3):373-9
pubmed: 24508508
Viral Immunol. 2020 Jan/Feb;33(1):61-70
pubmed: 31978319
J Proteome Res. 2017 Apr 7;16(4):1542-1555
pubmed: 28317380
Cells. 2019 Sep 29;8(10):
pubmed: 31569528
PLoS Pathog. 2023 Mar 28;19(3):e1011282
pubmed: 36976812
J Virol. 2017 May 12;91(11):
pubmed: 28298606
Trans R Soc Trop Med Hyg. 1952 Sep;46(5):509-20
pubmed: 12995440
PLoS Pathog. 2010 Jan 22;6(1):e1000732
pubmed: 20107601
J Infect Dis. 2018 Mar 28;217(8):1202-1213
pubmed: 29106643
BMC Neurosci. 2018 Feb 20;19(1):5
pubmed: 29463209
J Clin Virol. 2017 Sep;94:42-49
pubmed: 28753531
Front Immunol. 2021 Oct 21;12:750365
pubmed: 34745123
Front Cell Infect Microbiol. 2021 Aug 26;11:715208
pubmed: 34513730
Virus Res. 2018 Aug 2;254:34-40
pubmed: 28899653
Int J Mol Sci. 2019 Feb 28;20(5):
pubmed: 30823365
Sci Rep. 2017 Jan 27;7:41389
pubmed: 28128342
J Biol Chem. 2010 May 7;285(19):14071-7
pubmed: 20231296
Viruses. 2017 Apr 30;9(5):
pubmed: 28468299
Neuropathol Appl Neurobiol. 2016 Jun;42(4):317-25
pubmed: 27029817
Cell Host Microbe. 2018 Nov 14;24(5):731-742.e6
pubmed: 30439342
Development. 2017 Nov 15;144(22):4114-4124
pubmed: 28993398
J Virol. 2020 Oct 27;94(22):
pubmed: 32878890
J Virol Methods. 2006 Jun;134(1-2):183-9
pubmed: 16510196
Cell Host Microbe. 2016 Jul 13;20(1):83-90
pubmed: 27247001
Ann N Y Acad Sci. 2001 Sep;943:148-56
pubmed: 11594535
J Leukoc Biol. 2019 Sep;106(3):695-701
pubmed: 31063609
PLoS One. 2020 Dec 15;15(12):e0242367
pubmed: 33320867
Placenta. 2010 Nov;31(11):989-96
pubmed: 20850871
J Exp Med. 2021 Jan 4;218(1):
pubmed: 33075123
Cell Host Microbe. 2016 Aug 10;20(2):155-66
pubmed: 27443522
Arch Gynecol Obstet. 2021 Jul;304(1):91-100
pubmed: 33389093
Cells. 2019 Jul 15;8(7):
pubmed: 31311201
Nat Rev Microbiol. 2016 Nov;14(11):707-715
pubmed: 27573577
Methods Mol Biol. 2017;1527:311-320
pubmed: 28116726
J Cell Sci. 2009 Oct 15;122(Pt 20):3589-94
pubmed: 19812304
Vaccine. 2006 Feb 27;24(9):1421-6
pubmed: 16236402
J Gen Virol. 2010 Feb;91(Pt 2):394-403
pubmed: 19828759
Cell Stem Cell. 2016 Nov 3;19(5):663-671
pubmed: 27524440
Viruses. 2021 May 12;13(5):
pubmed: 34066055
Antiviral Res. 2018 Dec;160:38-47
pubmed: 30326204
Mediators Inflamm. 2018 Jun 3;2018:2450540
pubmed: 29967565
J Med Virol. 2016 Aug;88(8):1448-52
pubmed: 26792253
PLoS One. 2018 Jul 9;13(7):e0200086
pubmed: 29985932
Cell Host Microbe. 2016 May 11;19(5):705-12
pubmed: 27066743
Front Cell Infect Microbiol. 2022 Sep 12;12:979996
pubmed: 36171757
Annu Rev Immunol. 2018 Apr 26;36:279-308
pubmed: 29345964
Antiviral Res. 2018 Mar;151:55-62
pubmed: 29331320
PLoS Negl Trop Dis. 2018 Aug 20;12(8):e0006715
pubmed: 30125275
Front Immunol. 2019 Apr 15;10:792
pubmed: 31037072
J Med Virol. 2008 Jan;80(1):134-46
pubmed: 18041019

Auteurs

Mercedes Viettri (M)

Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City, Mexico.

Gerson Caraballo (G)

Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City, Mexico.

Maria Elena Sanchez (ME)

Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City, Mexico.

Aurora Espejel-Nuñez (A)

Research Division, National Institute of Perinatology, Mexico City, Mexico.

Abigail Betanzos (A)

Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City, Mexico.

Vianney Ortiz-Navarrete (V)

Department of Molecular Biomedicine, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City, Mexico.

Guadalupe Estrada-Gutierrez (G)

Research Division, National Institute of Perinatology, Mexico City, Mexico.

Porfirio Nava (P)

Department of Biophysical Physiology and Neuroscience, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City, Mexico.

Juan E Ludert (JE)

Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City, Mexico.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH